title: Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area.
abstract: OBJECTIVE
  To compare the risk-benefit ratio of intramuscular gold (gold sodium thiomalate (GST)) and methotrexate (MTX) in a population with rheumatoid arthritis (RA) from a deprived area.
  
  
  METHODS
  Patients with active RA were randomly assigned to open treatment with GST or MTX. Clinical and laboratory assessment was performed at 0, 12, 24, and 48 weeks. Results were analysed on an intention to treat basis.
  
  
  RESULTS
  141 patients were recruited-72 were randomly allocated to GST and 69 to MTX. There were no statistically significant differences found in either the clinical or demographic variables at baseline. At 48 weeks 31 (43%) patients continued to receive GST and 43 (62%) MTX. The median MTX dose achieved was 10 mg. Gold caused significantly more withdrawals for toxicity (43% GST v 19% MTX, p=0.0026, log rank test). Both groups experienced a significant improvement in erythrocyte sedimentation rate, C reactive protein, Ritchie Articular Index, and pain score by 24 weeks (p<0.001, Friedman test). Although a trend towards an improved Health Assessment Questionnaire (HAQ) score and global wellbeing was seen in both groups, this did not reach statistical significance. No differences in efficacy were found when the two groups were compared (Mann-Whitney).
  
  
  CONCLUSIONS
  GST and low dose MTX showed equivalent efficacy, but toxicity was more common in patients treated with GST. GST, although more toxic, remains a useful alternative for patients in whom MTX is contraindicated.
authors.affiliation: Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, G4 0SF, United Kingdom. jendh@email.msn.com
authors.forename: J
authors.initials: J
authors.lastname: Hamilton
authors.forename: I B
authors.initials: IB
authors.lastname: McInnes
authors.forename: E A
authors.initials: EA
authors.lastname: Thomson
authors.forename: D
authors.initials: D
authors.lastname: Porter
authors.forename: J A
authors.initials: JA
authors.lastname: Hunter
authors.forename: R
authors.initials: R
authors.lastname: Madhok
authors.forename: H A
authors.initials: HA
authors.lastname: Capell
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005492:Folic Acid / Q000097:blood; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006052:Gold Sodium Thiomalate / Q000009:adverse effects / Q000627:therapeutic use*; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010147:Pain Measurement; D011204:Poverty Areas; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D005938:Glucocorticoids; D006052:Gold Sodium Thiomalate; D005492:Folic Acid; D008727:Methotrexate